Article Figures & Data
Figures
- FIGURE 1.
Survival curves of untreated and treated mice.
- FIGURE 2.
(A) In vitro 177Lu-RM2 uptake assay after rapamycin treatment. (B) 68Ga-RM2 small-animal PET scans of PC-3 tumor–bearing mice (arrows) with and without 72 h of treatment with rapamycin. Biodistribution of tumor, muscle, and liver (C) and autoradiography of tumor samples with 125I-bombesin (D) from untreated and rapamycin-treated animals.
- FIGURE 3.
(A) In vitro therapy study evaluating effect of combination therapy in PC-3 cells. (B) Survival curves of untreated mice and mice treated with rapamycin alone, 177Lu-RM2 alone, or combination therapy. (C) Representative hematoxylin and eosin sections from kidneys of untreated mouse, mouse treated with 144 MBq of 177Lu-RM2, and mouse from combination-therapy group. Arrows demonstrate intact nephrons. Samples from both treated mice were obtained at conclusion of respective studies. Control sample was obtained 3 wk after start of treatment. ***P < 0.0001.
Tables
- TABLE 1
Biodistribution Results and Tumor–to–Normal Tissue Ratios of 177Lu-RM2 in Nude Mice Bearing PC-3 Tumors
Time (h) Organs 4 24 Blood 0.07 ± 0.02 0.01 ± 0.00 Heart 0.05 ± 0.02 0.02 ± 0.00 Liver 0.31 ± 0.01 0.16 ± 0.01 Spleen 0.11 ± 0.01 0.06 ± 0.01 Lung 0.10 ± 0.01 0.04 ± 0.01 Kidney 2.09 ± 0.19 0.88 ± 0.09 Stomach 0.51 ± 0.19 0.05 ± 0.02 Intestine 0.14 ± 0.03 0.04 ± 0.00 Adrenal 0.59 ± 0.11 0.49 ± 0.07 Pancreas 0.70 ± 0.12 0.11 ± 0.02 Muscle 0.03 ± 0.00 0.01 ± 0.01 Bone 0.12 ± 0.02 0.10 ± 0.03 Tumor 10.97 ± 0.99 4.66 ± 0.44 Tumor-to-nontumor ratios Tumor to blood 156.7 466 Tumor to liver 35.4 29.1 Tumor to kidney 5.3 5.3 Tumor to pancreas 15.7 42.4 Tumor to muscle 365.7 466 Data are %IA/g ± SD; n = 5.
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- SMER28 attenuates PI3K/mTOR signaling by direct inhibition of PI3K p110 delta
- Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer
- New Developments in Peptide Receptor Radionuclide Therapy
- Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors
- Molecular Imaging and Therapy with a Purpose: A Renaissance of Nuclear Medicine
- Radiopeptides for Imaging and Therapy: A Radiant Future
- In Vitro and In Vivo Application of Radiolabeled Gastrin-Releasing Peptide Receptor Ligands in Breast Cancer
- Cerenkov Luminescence Imaging for Radiation Dose Calculation of a 90Y-Labeled Gastrin-Releasing Peptide Receptor Antagonist